TOP > 外国特許検索 > Human antibody kappa type light chain complex-containing composition and method for producing same

Human antibody kappa type light chain complex-containing composition and method for producing same NEW

外国特許コード F170009203
整理番号 AF12-18WO
掲載日 2017年9月12日
出願国 欧州特許庁(EPO)
出願番号 14838038
公報番号 3037434
出願日 平成26年8月13日(2014.8.13)
公報発行日 平成28年6月29日(2016.6.29)
国際出願番号 JP2014071379
国際公開番号 WO2015025786
国際出願日 平成26年8月13日(2014.8.13)
国際公開日 平成27年2月26日(2015.2.26)
優先権データ
  • 特願2013-170414 (2013.8.20) JP
  • 2014WO-JP71379 (2014.8.13) WO
発明の名称 (英語) Human antibody kappa type light chain complex-containing composition and method for producing same NEW
発明の概要(英語) (EP3037434)
A human antibody º type light chain complex-containing composition includes a complex in which a human antibody º type light chain is bound to one or more kinds of metal ions selected from the group consisting of Group 10 elements, Group 11 elements, and Group 12 elements.
The human antibody º type light chain is a dimer, cysteines at C terminals of two human antibody º type light chains are bound to each other via the metal ion, and 0.1 mol or more of the metal ion is bound per 1 mol of the human antibody º type light chain.
特許請求の範囲(英語) [claim1]
1. A human antibody kappa type light chain complex-containing composition, comprising: a complex in which a human antibody kappa type light chain is bound to one or more kinds of metal ions selected from the group consisting of Group 10 elements, Group 11 elements, and Group 12 elements, wherein the human antibody kappa type light chain is a dimer, and cysteines at C terminals of two human antibody kappa type light chains are bound to each other via the metal ion, and wherein 0.1 mol or more of the metal ion is bound per 1 mol of the human antibody kappa type light chain.
[claim2]
2. The human antibody kappa type light chain complex-containing composition according to Claim 1,
wherein the metal ion is one or more selected from the group consisting of copper ion, nickel ion, zinc ion, gold ion, silver ion, and platinum ion.
[claim3]
3. The human antibody kappa type light chain complex-containing composition according to Claim 1 or 2,
wherein the human antibody kappa type light chain is selected from the group consisting of: (1) a polypeptide in which a variable region is represented by an amino acid sequence of SEQ ID NO. 1 or an amino acid sequence obtained by substituting, adding or deleting one or several amino acids in the amino acid sequence; (2) a polypeptide in which a variable region is represented by an amino acid sequence of SEQ ID NO. 3 or an amino acid sequence obtained by substituting, adding or deleting one or several amino acids in the amino acid sequence; (3) a polypeptide in which a variable region is represented by an amino acid sequence of SEQ ID NO. 5 or an amino acid sequence obtained by substituting, adding or deleting one or several amino acids in the amino acid sequence; (4) a polypeptide in which a variable region is represented by an amino acid sequence of SEQ ID NO. 7 or an amino acid sequence obtained by substituting, adding or deleting one or several amino acids in the amino acid sequence; (5) a polypeptide in which a variable region is represented by an amino acid sequence of SEQ ID NO. 9 or an amino acid sequence obtained by substituting, adding or deleting one or several amino acids in the amino acid sequence; (6) a polypeptide in which a variable region is represented by an amino acid sequence of SEQ ID NO. 11 or an amino acid sequence obtained by substituting, adding or deleting one or several amino acids in the amino acid sequence; (7) a polypeptide in which a variable region is represented by an amino acid sequence of SEQ ID NO. 13 or an amino acid sequence obtained by substituting, adding or deleting one or several amino acids in the amino acid sequence; (8) a polypeptide in which a variable region is represented by an amino acid sequence of SEQ ID NO. 15 or an amino acid sequence obtained by substituting, adding or deleting one or several amino acids in the amino acid sequence; (9) a polypeptide in which a variable region is represented by an amino acid sequence of SEQ ID NO. 17 or an amino acid sequence obtained by substituting, adding or deleting one or several amino acids in the amino acid sequence; (10) a polypeptide in which a variable region is represented by an amino acid sequence of SEQ ID NO. 19 or an amino acid sequence obtained by substituting, adding or deleting one or several amino acids in the amino acid sequence; (11) a polypeptide in which a variable region is represented by an amino acid sequence of SEQ ID NO.21 or an amino acid sequence obtained by substituting, adding or deleting one or several amino acids in the amino acid sequence; (12) a polypeptide in which a variable region is represented by an amino acid sequence of SEQ ID NO. 23 or an amino acid sequence obtained by substituting, adding or deleting one or several amino acids in the amino acid sequence; (13) a polypeptide in which a variable region is represented by an amino acid sequence of SEQ ID NO. 25 or an amino acid sequence obtained by substituting, adding or deleting one or several amino acids in the amino acid sequence; (14) a polypeptide in which a variable region is represented by an amino acid sequence of SEQ ID NO. 27 or an amino acid sequence obtained by substituting, adding or deleting one or several amino acids in the amino acid sequence; (15) a polypeptide which is represented by an amino acid sequence in which 219 **th cysteine in an amino acid sequence of SEQ ID NO. 2 is substituted with alanine or by an amino acid sequence obtained by substituting, adding or deleting one or several amino acids in the amino acid sequence; (16) a polypeptide in which a variable region is represented by an amino acid sequence of SEQ ID NO. 29 or an amino acid sequence obtained by substituting, adding or deleting one or several amino acids in the amino acid sequence; (17) a polypeptide in which a variable region is represented by an amino acid sequence of SEQ ID NO. 31 or an amino acid sequence obtained by substituting, adding or deleting one or several amino acids in the amino acid sequence; (18) a polypeptide in which a variable region is represented by an amino acid sequence of SEQ ID NO. 33 or an amino acid sequence obtained by substituting, adding or deleting one or several amino acids in the amino acid sequence; (19) a polypeptide in which a variable region is represented by an amino acid sequence of SEQ ID NO. 35 or an amino acid sequence obtained by substituting, adding or deleting one or several amino acids in the amino acid sequence; (20) a polypeptide in which a variable region is represented by an amino acid sequence of SEQ ID NO. 37 or an amino acid sequence obtained by substituting, adding or deleting one or several amino acids in the amino acid sequence; (21) a polypeptide in which a variable region is represented by an amino acid sequence of SEQ ID NO. 39 or an amino acid sequence obtained by substituting, adding or deleting one or several amino acids in the amino acid sequence; (22) a polypeptide in which a variable region is represented by an amino acid sequence of SEQ ID NO. 41 or an amino acid sequence obtained by substituting, adding or deleting one or several amino acids in the amino acid sequence; (23) a polypeptide in which a variable region is represented by an amino acid sequence of SEQ ID NO. 43 or an amino acid sequence obtained by substituting, adding or deleting one or several amino acids in the amino acid sequence; (24) a polypeptide in which a variable region is represented by an amino acid sequence of SEQ ID NO. 45 or an amino acid sequence obtained by substituting, adding or deleting one or several amino acids in the amino acid sequence; (25) a polypeptide in which a variable region is represented by an amino acid sequence of SEQ ID NO. 47 or an amino acid sequence obtained by substituting, adding or deleting one or several amino acids in the amino acid sequence; (26) a polypeptide in which a variable region is represented by an amino acid sequence of SEQ ID NO. 49 or an amino acid sequence obtained by substituting, adding or deleting one or several amino acids in the amino acid sequence; and (27) a polypeptide in which a variable region is represented by an amino acid sequence of SEQ ID NO. 51 or an amino acid sequence obtained by substituting, adding or deleting one or several amino acids in the amino acid sequence.
[claim4]
4. A pharmaceutical composition, comprising the human antibody kappa type light chain complex-containing composition according to any one of Claims 1 to 3 as an active ingredient.
[claim5]
5. The pharmaceutical composition according to Claim 4, which is an anti-cancer drug.
[claim6]
6. A method of producing a human antibody kappa type light chain complex-containing composition, comprising: an expression process of expressing a human antibody kappa type light chain by an intracellular or extracellular expression system using an expression vector including a polynucleotide encoding the human antibody kappa type light chain having cysteine residue at the C terminal thereof; and a purification process of purifying the human antibody kappa type light chain from the expression product obtained in the expression process, wherein, (a) the human antibody kappa type light chain is expressed in the presence of one or more kinds of metal ions selected from the group consisting of Group 10 elements, Group 11 elements, and Group 12 elements in the expression process, or (b) the human antibody kappa type light chain is purified from a mixture obtained by adding one or more kinds of metal ions selected from the group consisting of Group 10 elements, Group 11 elements, and Group 12 elements to the expression product obtained in the expression process.
[claim7]
7. The method of producing a human antibody kappa type light chain complex-containing composition according to Claim 6,
wherein, in (b), the human antibody kappa type light chain is purified from the mixture after incubating the mixture for 30 minutes to 48 hours.
[claim8]
8. The method of producing a human antibody kappa type light chain complex-containing composition according to Claim 6 or 7,
wherein the purification process includes: a first purification process of obtaining a crude purified product containing the human antibody kappa type light chain from the expression product obtained from the expression process by column chromatography using a column containing a first filler; and a second purification process of obtaining a purified product of the human antibody kappa type light chain from the crude purified product obtained from the first purification process by column chromatography using a column containing a second filler, and wherein the metal ion is added to the crude purified product before the second purification process after the first purification process.
[claim9]
9. The method of producing a human antibody kappa type light chain complex-containing composition according to Claim 8,
wherein, before the second purification process, the crude purified product, to which the metal ion has been added, is incubated for 30 minutes to 48 hours.
[claim10]
10. The method of producing a human antibody kappa type light chain complex-containing composition according to Claim 8 or 9,
wherein the metal ion is added into the expression system in the expression process, and is further added to the crude purified product before the second purification process after the first purification process.
[claim11]
11. A method of producing a human antibody kappa type light chain complex-containing composition,
wherein a human antibody kappa type light chain is incubated in a solution containing one or more kinds of metal ions selected from the group consisting of Group 10 elements, Group 11 elements, and Group 12 elements to produce a composition containing a complex in which cysteine residues at C terminals of two human antibody kappa type light chains are bound to each other via the metal ion.
  • 出願人(英語)
  • JAPAN SCIENCE AND TECHNOLOGY AGENCY
  • 発明者(英語)
  • UDA TAIZO
  • HIFUMI EMI
国際特許分類(IPC)
指定国 (EP3037434)
Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Extension States: BA ME
参考情報 (研究プロジェクト等) CREST Establishment of Innovative Manufacturing Technology Based on Nanoscience AREA
ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close